Geraldine Henwood - 15 Dec 2021 Form 4 Insider Report for Baudax Bio, Inc.

Role: President and CEO, Director
Signature: By: /s/ Richard Casten, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Dec 2021
Net transactions value: -$5,777
Form type: 4
Filing time: 23 Dec 2021, 16:45:13 UTC
Previous filing: 14 Dec 2021
Next filing: 17 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BXRX	Common Stock	Tax liability	$5,777	-18,636	-5.2%	$0.3100	336,716	15 Dec 2021	Direct	F1
holding	BXRX	Common Stock						20,000	15 Dec 2021	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BXRX	Stock Option (right to buy)	Award	$0	+821,168		$0.000000	821,168	22 Dec 2021	Common Stock	821,168	$1.70	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units.
F2	The Option was granted on January 20, 2021, contingent upon the Company's board of directors approval of the increase in the number of shares available for issuance under the Company's 2019 Equity Incentive Plan pursuant to the evergreen provision therein.
F3	The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2021, subject to continued service to the Company.